284620 — Kainos Medicine Income Statement
0.000.00%
Last trade - 00:00- KR₩39bn
- KR₩42bn
- KR₩590m
Annual income statement for Kainos Medicine, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 1,662 | 130 | 267 | 590 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 1,660 | 91 | 205 | 422 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 9,386 | 12,882 | 14,150 | 17,056 | 13,281 |
| Operating Profit | -9,386 | -11,219 | -14,020 | -16,789 | -12,691 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -12,763 | -16,224 | -15,913 | -15,238 | -12,189 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -11,448 | -16,225 | -15,914 | -15,239 | -12,190 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -11,448 | -16,212 | -15,881 | -15,235 | -12,190 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -11,448 | -16,212 | -15,881 | -15,235 | -12,190 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -511 | -695 | -724 | -561 | -424 |
| Dividends per Share |